Introduction
Despite public awareness warning against increased sun exposure, cutaneous melanoma continues to be one of the leading causes of death of all the skin cancers. Both incidence and mortality rates have increased steadily worldwide [1] . Significant advances in adjuvant therapies have been made in the past ten years. One of the earliest publications documenting prognostic factors in patients with melanoma was published thirty five years ago, and tumor thickness, along with anatomical site, were felt to be dominant factors [2] . Additional factors included: pigmentation, lymphocyte infiltration, growth pattern and regression; however, these factors were found to have either indirect or no influence on survival. In 2001, the American Joint Committee on Cancer proposed major revisions on the staging system, and with the aid of a multi-institutional effort, several key prognostic indicators for melanoma were agreed upon; tumor thickness, ulceration, presence of positive lymph nodes, and visceral versus non visceral metastatic disease [3] . Accurately predicting prognosis aids in guiding appropriate management, determining the need for further investigation, and to assign risk status for patients that may benefit from closer surveillance, adjuvant therapy, or consideration for a clinical trial [1] .
The presence of tumor infiltrating lymphocytes (TIL) and their roles as a prognostic indicator for malignant melanomas has been a topic of much controversy. There currently is no consensus regarding the presences of TIL in melanoma; nonetheless, the general trend suggests that tumor infiltrating lymphocytes portend an added survival benefit. Tumor infiltrating lymphocytes are histopathological markers of the host immune response to melanoma [4] . Several studies have been able to correlate the presence of TIL with improved overall survival [1, [4] [5] [6] , however others have found no such relationship [7, 8] . There have been numerous prognostic indicators that are known to play a role in melanoma, and depth of invasion has been one of the most sensitive factors [2] . As advances have been made, the presence of ulceration, mitosis, and sentinel lymph node positivity have added even more information on outcomes [3] . As much controversy continues to exist regarding tumor infiltrating lymphocytes as a potential mediator in prognosis, we aimed to evaluate if TILs correlated with prognosis in patients with malignant melanoma.
Methods
We performed an IRB approved retrospective analysis on 241 patients treated at a tertiary cancer center from 2009-2011. We compared the absence or presence of tumor infiltrating lymphocytes correlated to preoperative white blood cells counts, age, tumor depth, mitotic rates, sentinel lymph node positivity and pathological stage. Tumor infiltrating lymphocytes were quantified by hematoxylin and eosin (H&E) staining by an experienced dermatopathologist. They were globally characterized as being absent or present. They were further sub-classified, if able, into brisk or non-brisk categories. The primary aim of our study was to identify if the presence of TIL served as a reliable indicator to predict aggressive tumor biology, and to review the literature comparing TIL and melanoma, as both a prognostic indicator, and a potential modality for treatment.
Results
Patient distribution was fairly equal between male and female, and the average age slightly older for men at 63, compared to 59 for women. The overwhelming majority of patients were Caucasian, at 93%. Anatomical site of the melanoma varied from the upper extremity, lower extremity, head and neck, trunk or genitourinary regions. The majority of the lesions were found to be on the trunk, followed by the extremities (Table 1) . Preoperative biopsies were performed by a shave, excision or punch method. Pathological staging ranged from in-situ lesions to patients with stage IV disease. Of the patients with pathological staging available, 5% were diagnosed with in-situ disease, 23% IA, 25% IB, 22% II, 8% IIIA, 6% IIIB, 6% IIIC, and 5% IV.
A wide array of tumor biology was seen, ranging from superficial spreading, nodular, acral, lentigo, metastatic, in-situ, and a sub-set of unknown. The superficial spreading variant was seen in 38%, nodular in 12%, lentigo in 9%, and acral in 3% of the population. Fifteen percent of the patients had thick melanomas over 4 mm in depth. Fifty-two percent of patients had mitotic rates between 1-4 mm 2 , and 22% had ulceration. The presence of tumor infiltrating lymphocytes was determined by a single pathologist, and was categorized as either being absent or present. When present, they were subdivided into classifications of brisk or non-brisk. Forty-two percent of patients had no TIL present, 32% had TIL present, and in 25% TIL status was not recorded (Table 2 ) (Figure 1 and 2). Of the patients found to have superficial spreading, 42% had absent TIL, 8% brisk, and 28% nonbrisk. The remaining 22% were recorded as being present, with no specification on type of TIL, or not reported. Of the cohort found to have a nodular type, 46% had absent TIL, 4% brisk, and 39% nonbrisk. The remaining 11% were not recorded.
Only 15% of the patients had thick melanomas greater than 4 mm. Patients with thin melanomas were found to have TIL in 48% versus 22% with thick melanomas, suggesting a potential indicator for prognosis (p=0.020). Mitotic rate has been a proven indicator for prognosis, with higher rates leading to decreased survival [9] . Attempts were made to correlate mitosis with the presence or absence of TIL. When TIL was identified, 8% of patients had mitosis > 4 mm 2 , and 14% when TIL was absent. Although not reaching statistical significance, the trend suggests that presence of TIL may be associated with lower mitotic rates, and thus improved survival. Similar to mitosis, sentinel lymph node positivity has been found to correlate with worse survival trends [10] . This was corroborated in our study, showing that positive sentinel lymph nodes were found in 31% versus 21% of patients when mitosis was > 4 mm 2 (p=0.001). When comparing lymph node positivity, TIL was identified in 38% of patients, and negative node status yielded the presence of TIL in 21% (p=0.388); as such, no correlation can be made between lymph node positivity and TIL.
Comparisons were made independently between the presence of TIL, degree of mitosis and survival, to overall stage. The presence of TIL did not correlate with an earlier staged melanoma (p=0.294); when the degree of mitosis were compared, a strong correlation was found to stage (p=<0.001). Independently, the presence of TIL did not correlate with increased survival (p=0.140) (Figure 3) . Using multivariate analysis, stage was compared to both TIL and mitotic rate; however no statistical significance was found when compared to mitotic rate alone (p=0.39). The only association of TIL to prognosis that was found in our series was the trend for TIL to be identified in thinner melanomas. When comparing TIL with mitosis, SLNs, and early staged melanomas, there was no statistical significance to (20) 57 (24) 21 (8) 104 (43) 5 (2) 7 (3) suggest benefit as a reliable prognostic indicator.
Discussion
The prognostic significance of tumor infiltrating lymphocytes in patients with melanoma remains controversial. It is believed that the number of TIL may be indicative of a potent immune response against tumor antigens, and therefore portend a more favorable prognosis. One could hypothesize that TIL may be altered in older patients.
While our study found that high numbers of TIL were inversely related to tumor depth of invasion, the degree of T-cell infiltration of the tumor was not correlated with survival benefit. Balch et al. were found to be independent prognostic factors of 5-year survival.
In patients with stage I disease, TIL concentration was inversely correlated with tumor thickness (P=0.003), however differences in TIL magnitude and depth of invasion did not have an impact on survival [2] . Burton et al. studied 515 patients where TIL responses were classified as being brisk and non-brisk. Using multivariate analysis, a brisk TIL response was not found to be a significant independent factor for disease-free survival [6] .
On the contrary, several studies reported in the literature have found a positive correlation with TILs as a prognostic indicator in melanoma. Grotz et al. performed a retrospective study of 250 patients, and found that non-brisk or absent TIL was independently associated with recurrence (P< 0.0001), decreased 5-year diseasefree survival (76 vs. 91%, P = 0.0006), as well as, a decreased 5-year melanoma-specific survival (82 vs. 95%, P=0.0008) [11] . Knol et al. suggested a benefit in both progression free survival (PFS) and overall survival (OS) with the presence of tumor reactive T cells, which was increased with the injection of melanoma reactive TIL (PFS: p=0.00289 and OS: p=0.00279) [12] . Although our series did not find a relationship between TIL and stage, earlier stage III tumors were associated with a greater number of tumor-reactive T cells than late stage III tumors [12] .
In a study stratifying TIL classification, Mihm et al. examined the histology from 99 resected metastatic lymph nodes. The pattern of TIL was investigated and 16 tumors were classified as brisk, 37 as non-brisk, and 46 as absent. The disease-free survival was 81.3% for brisk cases, 46.8% for non-brisk cases, and 29.3% for absent groups (P=0.007) [13] . This suggests that patients, who express TIL, versus those who express none at all, do have improved survival. The results of this study are similar to the results published by Clark et al., who showed that the 8-year survival rate for patients with melanoma was 88.5% when TIL were brisk, 75% for non-brisk, and 59.3% for absent [14] . Clemente et al. published 5-year survival rates for patients with melanomas following similar patterns; 77% for brisk, 53% for nonbrisk, and 37% for absent [5] .
Although it is evident that patients with TIL seem to have better survival than when absent, there continues to be no standardized means of pathological analysis to classifying tumor infiltrating lymphocytes. Busam et al. performed a study which found that educating pathologists on how to prepare and analyze specimens allowed for more precise identification of TILs [15] . The current terminology for the classification and description of TIL deposits as "brisk", "non-brisk" and "absent," has also been challenged. It has been suggested that terms such as "diffuse" versus "focal" may be more accurate, and could potentially facilitate better reproducibility [15] .
Questions have arisen regarding the specific TIL antigen receptor, and how that may influence overall prognosis. As the role of TILs remains uncertain, one fact remains true, that immune response likely plays a critical role. A variety of studies have looked into TIL antigen receptor structure and the antigen to which melanoma-specific T cells react. Recent data has revealed that the composition of TIL is not homogenous, but rather comprised of many lymphocytic subsets [16] . Although the majority of the aforementioned studies correlate TIL to lymph node positivity, depth of invasion, and even survival; few studies have looked into the specific immunophenotype of TILs.
As the majority of research deals with immunology, hypothesizes have been made linking impaired lymphatic function, which may be more prominent in the elderly, to the lack of melanoma cells from spreading to the SLN. This could potentially prevent the induction of the adaptive immune response to the melanoma, manifested as a non-brisk or absent TIL response [11] . Our series tried to find a correlate between the elderly, WBC, and the presence or absence of TIL, however no statistical significance was reached. These findings suggest that more research needs to occur; looking into the composition and function of TIL before conclusions can be made.
It has been established that TIL plays some role with overall prognosis in patients with melanoma. Depending on what type of TIL, "brisk," "non-brisk," or "absent," each can affect survival differently.
A new area that has brought much excitement to the field is the use of immunotherapy. Immunotherapy using TIL was first described in 1988 and has emerged as a promising treatment option for metastatic melanoma. Mature lymphocytes specific to the tumor antigen are isolated in vitro, processed, cultured and re-infused, allowing for targeted therapy.
A variety of cells participate in the immune response against the tumor. CD8 + , CD4
+ T cells, B cells, NK, and innate type T cells expressing the γδ TCR have been described as playing a role in TIL [17] . It appears that the main cells are CD-8 + T cells, demonstrating critical effects in anti-tumor response, known to mediate the antigenspecific cytolysis of cancerous cells [17, 18] . The role of CD4 + cells is debatable but studies have shown that they might have a role in the adaptive immunity, and may also play a role in a small percentage of patients in which CD4
+ dominant TIL were found [18] [19] [20] . Different techniques have been suggested to improve the isolation and expansion of the lymphocytes. Some examples include the "young TIL" protocol, lymphodepletion, irradiation, trogocytosis, and the use of IL-2, IFN-γ or other co-stimulatory molecules [17, [21] [22] [23] [24] [25] [26] .
Another interesting area revolves on the discovery of corticotropin-releasing factors, and there involvement in the "skin stress response system". It is well documented that CRFR-1 receptors are expressed in melanoma, so targeting of this is a rational approach to treatment of this disease [27] . Slominsky et al. proved on immunohistochemistry that CFR and CRFR-1 were detected in melanoma specimen, however differences in their expression level did not correlate to melanoma progression [27] . Again we see a potential tool for measuring prognosis in patients with melanoma fall short. Taking a step back, we should look at the skin as a natural immune barrier to toxins in the environment. The skin is a steroidogenic organ which can regulate local and systemic immune activities. Dysregulation of cutaneous steroidogenesis could be linked to various skin diseases [28] . An example of another epidermal product that has been shown to be involved with melanomas is pro-opiomelanocortin (POMC). It is suggested that progression of melanoma is associated with increased POMC-peptide expression due to generation of a "tumor-favorable environment" [27] . The use of POMC in determining if the melanoma is progressing on or off therapy seems promising. Steroidogenesis is not the only method which affects melanogenesis. L-tyrosine and L-DOPA have also been studied as intermediates that affect melanogenesis. Slominsky et al. reports that in addition to serving as substrates and intermediates for melanogenesis, L-tyrosine and L-DOPA also act as inducers and positive regulators of the melanogenic pathway [29] . Therapies directed to control regulators of melanogenesis could lead to new drugs that fight melanoma at the immunogenic level.
Many factors have been shown to affect the efficacy of TIL therapy. It has been observed that the age and gender of patients, as well as stage and primary site of tumor play a role [11, 12, 25, 30, 31] . In addition, the temporal relationship of systemic therapy to the time of resection, the number of activated lymphocytes, and the expansion rate of the cells isolated from the patient impact efficacy [11, 31, 32] . The role of TIL in the treatment of melanoma is currently in clinical trials, and results appear promising. Further research is currently being done in order to elucidate the exact role and the optimal timing for TIL. Additional studies need to be done so protocols can be established to make this potentially life-saving therapy more accessible and cost effective.
There remains inconsistency in the literature as to the prognostic significance of TIL in melanoma. The overwhelming majority of these studies are retrospective in nature, and there are few randomized prospective trials investigating the relationship between TIL and prognosis. It has been well established that tumor thickness, lymph node involvement, and the presence of ulcerations are key prognostic indicators. From current literature, results have been published stating that the presence of TIL provides for a better prognosis, and increased 5-year survival rates; however just as many articles say the contrary. Results suggest that TIL may in fact predict sentinel lymph node positivity, but then no significance is found for survival benefit. Each study obviously carries its own flaws and biases. After a thorough review of the literature, our series suggests that the use of tumor infiltrating lymphocytes as a prognostic factor for cutaneous melanoma shows no statistical significance when compared to mitosis, SLN status or early staged melanomas. Our results support the current standards of mitotic rates, lymph node positivity, and depth of invasion as independent predictors of prognosis, with further research needed to elucidate the true significance of TIL.
